 |
|
|
|
 |
|
|
|
| Article 1 to 7 out of 7 concerning Cancer Research UK
|
-
Eden Biodesign selected by Cancer Research UK to develop and manufacture two therapeutic candidates
(09/06/2007)
Treatment of advanced intra-abdominal and head and neck cancer
Eden Biodesign Ltd announced that it has signed agreements with Cancer Research UK (CR-UK) to provide consultancy, process development and manufacturing services for two of CR-UK's leading gene therapy products: Ad-hTR-NTR for advanced ...
-
British doctors to start new phase III trial with Pharmexa's GV1001
(03/19/2007)
A Phase III trial testing a new treatment for pancreatic cancer has now been initiated. Pharmexa has developed the drug and is co-financing the trial together with pharmaceuticals company Roche and Cancer Research UK.Referred to as the TeloVac ...
-
VASTox joins European research consortium to target the development of new treatments for cancer
(01/19/2007)
Research will focus on Cancer Stem Cells as target for new therapies
VASTox announced that it has become a partner in a new European consortium that will undertake research towards developing new treatments for cancer. The research programme, called Targeting Cancer Stem Cells for Therapy, will be backed by a EUR2 ...
-
Cancer Research UK, GATC Biotech and DNASTAR sign Lasergene Site License Agreement
(10/30/2006)
GATC Biotech, the Cancer Research UK and DNASTAR, Inc. signed a broad license agreement for the Lasergene sequence analysis software developed by DNASTAR and distributed and supported by GATC.Under the three year site license, the software will be ...
-
Illumina To Conduct Large-Scale Genotyping For Uk-Based Research Groups Studying Molecular Basis Of Prostate Cancer
(04/13/2006)
llumina, Inc. announced that it has signed a genotyping services agreement to support prostate cancer researchers funded by Cancer Research UK. Under the terms of the agreement, valued at nearly $7 million, Illumina's service group will conduct ...
-
Viragen Licenses 'Anti-CD55 Antibody' Cancer Therapy from Cancer Research Technology
(05/11/2005)
Viragen, Inc. and Cancer Research Technology Limited (U.K.) announced a license agreement that provides Viragen with worldwide exclusive rights to commercialize the anti-CD55 antibody, which is currently in preclinical development for the treatment ...
-
Cancer Research UK Adopts Dharmacon Gene-Silencing Technology
(04/21/2005)
Dharmacon, Inc. announced an agreement to provide siRNA libraries to Cancer Research UK. The siRNA libraries, which were developed using Dharmacon's proprietary SMARTselection(TM) and SMARTpoolŽ technology platforms, initially include protein kinase ...
|
|
|
Top